

Open Peer Review on Qeios

Eculizumab

National Cancer Institute

Source

National Cancer Institute. <u>Eculizumab</u>. NCI Thesaurus. Code C48386.

A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)

Qeios ID: CBB3TB · https://doi.org/10.32388/CBB3TB